Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer.
Norris JD, Ellison SJ, Baker JG, Stagg DB, Wardell SE, Park S, Alley HM, Baldi RM, Yllanes A, Andreano KJ, Stice JP, Lawrence SA, Eisner JR, Price DK, Moore WR, Figg WD, McDonnell DP. Norris JD, et al. Among authors: eisner jr. J Clin Invest. 2017 Jun 1;127(6):2326-2338. doi: 10.1172/JCI87328. Epub 2017 May 2. J Clin Invest. 2017. PMID: 28463227 Free PMC article.
Phase 2 Study of Seviteronel (INO-464) in Patients With Metastatic Castration-Resistant Prostate Cancer After Enzalutamide Treatment.
Madan RA, Schmidt KT, Karzai F, Peer CJ, Cordes LM, Chau CH, Steinberg SM, Owens H, Eisner J, Moore WR, Dahut WL, Gulley JL, Figg WD. Madan RA, et al. Clin Genitourin Cancer. 2020 Aug;18(4):258-267.e1. doi: 10.1016/j.clgc.2019.11.002. Epub 2020 Mar 29. Clin Genitourin Cancer. 2020. PMID: 32327394 Free PMC article. Clinical Trial.
Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer.
Bardia A, Gucalp A, DaCosta N, Gabrail N, Danso M, Ali H, Blackwell KL, Carey LA, Eisner JR, Baskin-Bey ES, Traina TA. Bardia A, et al. Among authors: eisner jr. Breast Cancer Res Treat. 2018 Aug;171(1):111-120. doi: 10.1007/s10549-018-4813-z. Epub 2018 May 9. Breast Cancer Res Treat. 2018. PMID: 29744674 Free PMC article. Clinical Trial.
Seviteronel, a Novel CYP17 Lyase Inhibitor and Androgen Receptor Antagonist, Radiosensitizes AR-Positive Triple Negative Breast Cancer Cells.
Michmerhuizen AR, Chandler B, Olsen E, Wilder-Romans K, Moubadder L, Liu M, Pesch AM, Zhang A, Ritter C, Ward ST, Santola A, Nyati S, Rae JM, Hayes D, Feng FY, Spratt D, Wahl D, Eisner J, Pierce LJ, Speers C. Michmerhuizen AR, et al. Front Endocrinol (Lausanne). 2020 Feb 11;11:35. doi: 10.3389/fendo.2020.00035. eCollection 2020. Front Endocrinol (Lausanne). 2020. PMID: 32117061 Free PMC article.
A population pharmacokinetic analysis of the oral CYP17 lyase and androgen receptor inhibitor seviteronel in patients with advanced/metastatic castration-resistant prostate cancer or breast cancer.
Peer CJ, Schmidt KT, Kindrick JD, Eisner JR, Brown VV, Baskin-Bey E, Madan R, Figg WD. Peer CJ, et al. Among authors: eisner jr. Cancer Chemother Pharmacol. 2019 Oct;84(4):759-770. doi: 10.1007/s00280-019-03908-0. Epub 2019 Jul 31. Cancer Chemother Pharmacol. 2019. PMID: 31367790 Free PMC article.
Expression of the Androgen Receptor Governs Radiation Resistance in a Subset of Glioblastomas Vulnerable to Antiandrogen Therapy.
Werner CK, Nna UJ, Sun H, Wilder-Romans K, Dresser J, Kothari AU, Zhou W, Yao Y, Rao A, Stallard S, Koschmann C, Bor T, Debinski W, Hegedus AM, Morgan MA, Venneti S, Baskin-Bey E, Spratt DE, Colman H, Sarkaria JN, Chinnaiyan AM, Eisner JR, Speers C, Lawrence TS, Strowd RE, Wahl DR. Werner CK, et al. Among authors: eisner jr. Mol Cancer Ther. 2020 Oct;19(10):2163-2174. doi: 10.1158/1535-7163.MCT-20-0095. Epub 2020 Aug 12. Mol Cancer Ther. 2020. PMID: 32796101 Free PMC article.
28 results